Histone Deacetylase Inhibitors Target the Leukemic Microenvironment by Enhancing a Nherf1-Protein Phosphatase 1α-TAZ Signaling Pathway in Osteoblasts

Advances in understanding the leukaemia microenvironment

(2014) Yoko Tabe et al.   BRITISH JOURNAL OF HAEMATOLOGY

A phase 1 clinical trial of vorinostat in combination with decitabine in patients with acute myeloid leukaemia or myelodysplastic syndrome

(2014) Mark Kirschbaum et al.   BRITISH JOURNAL OF HAEMATOLOGY

Canonical Wnt signalling activates TAZ through PP1A during osteogenic differentiation

(2014) M R Byun et al.   CELL DEATH AND DIFFERENTIATION

The Hippo pathway effectors TAZ and YAP in development, homeostasis and disease

(2014) X. Varelas   DEVELOPMENT

(−)-Epicatechin Gallate (ECG) Stimulates Osteoblast Differentiation via Runt-related Transcription Factor 2 (RUNX2) and Transcriptional Coactivator with PDZ-binding Motif (TAZ)-mediated Transcriptional Activation

(2014) Mi Ran Byun et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Histone Deacetylase Inhibition Destabilizes the Multi-Potent State of Uncommitted Adipose-Derived Mesenchymal Stromal Cells

(2014) Amel Dudakovic et al.   JOURNAL OF CELLULAR PHYSIOLOGY

Leukaemogenesis induced by an activating β-catenin mutation in osteoblasts

(2014) Aruna Kode et al.   NATURE

The Biology of YAP/TAZ: Hippo Signaling and Beyond

(2014) Stefano Piccolo et al.   PHYSIOLOGICAL REVIEWS

Translational Phase I Trial of Vorinostat (Suberoylanilide Hydroxamic Acid) Combined with Cytarabine and Etoposide in Patients with Relapsed, Refractory, or High-Risk Acute Myeloid Leukemia

(2013) I. Gojo et al.   CLINICAL CANCER RESEARCH

CXCR4 Chemokine Receptor Signaling Induces Apoptosis in Acute Myeloid Leukemia Cells via Regulation of the Bcl-2 Family Members Bcl-XL, Noxa, and Bak

(2013) Kimberly N. Kremer et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Histone Deacetylase Inhibition Promotes Osteoblast Maturation by Altering the Histone H4 Epigenome and Reduces Akt Phosphorylation

(2013) Amel Dudakovic et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Osteoblasts Protect AML Cells From SDF-1-Induced Apoptosis

(2013) Kimberly N. Kremer et al.   JOURNAL OF CELLULAR BIOCHEMISTRY

Differential regulation of myeloid leukemias by the bone marrow microenvironment

(2013) Daniela S Krause et al.   NATURE MEDICINE

The two faces of Hippo: targeting the Hippo pathway for regenerative medicine and cancer treatment

(2013) Randy Johnson et al.   NATURE REVIEWS DRUG DISCOVERY

Vorinostat Induces Apoptosis and Differentiation in Myeloid Malignancies: Genetic and Molecular Mechanisms

(2013) Gabriela Silva et al.   PLoS One

Ajuba Family Proteins Link JNK to Hippo Signaling

(2013) G. Sun et al.   Science Signaling

Can we improve outcomes in patients with acute myelogenous leukemia? Incorporating HDAC inhibitors into front-line therapy

(2012) Guillermo Garcia-Manero   BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY

Regulation of protein phosphatase 1 by intrinsically disordered proteins

(2012) Meng S. Choy et al.   BIOCHEMICAL SOCIETY TRANSACTIONS

Osteopontin is a prognostic factor for survival of acute myeloid leukemia patients

(2012) R. Liersch et al.   BLOOD

Human extramedullary bone marrow in mice: a novel in vivo model of genetically controlled hematopoietic microenvironment

(2012) Y. Chen et al.   BLOOD

NHERF1 regulation of PTH-dependent bimodal Pi transport in osteoblasts

(2012) Bin Wang et al.   BONE

Na+/H+Exchanger Regulatory Factor 1 (NHERF1) Directly Regulates Osteogenesis

(2012) Li Liu et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Phase II Trial of Vorinostat With Idarubicin and Cytarabine for Patients With Newly Diagnosed Acute Myelogenous Leukemia or Myelodysplastic Syndrome

(2012) Guillermo Garcia-Manero et al.   JOURNAL OF CLINICAL ONCOLOGY

p53 activation of mesenchymal stromal cells partially abrogates microenvironment-mediated resistance to FLT3 inhibition in AML through HIF-1 -mediated down-regulation of CXCL12

(2011) K. Kojima et al.   BLOOD

Suberoylanilide hydroxamic acid (SAHA; vorinostat) causes bone loss by inhibiting immature osteoblasts

(2011) Meghan E. McGee-Lawrence et al.   BONE

TAZ is required for the osteogenic and anti-adipogenic activities of kaempferol

(2011) Mi Ran Byun et al.   BONE

Vorinostat Induces Reactive Oxygen Species and DNA Damage in Acute Myeloid Leukemia Cells

(2011) Luca A. Petruccelli et al.   PLoS One

Vorinostat in acute myeloid leukemia and myelodysplastic syndromes

(2010) Thomas Prebet et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

PP1 Cooperates with ASPP2 to Dephosphorylate and Activate TAZ

(2010) Chen-Ying Liu et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Bone progenitor dysfunction induces myelodysplasia and secondary leukaemia

(2010) Marc H. G. P. Raaijmakers et al.   NATURE

Therapeutic targeting of microenvironmental interactions in leukemia: Mechanisms and approaches

(2009) Marina Konopleva et al.   DRUG RESISTANCE UPDATES

Ephrin B1 Regulates Bone Marrow Stromal Cell Differentiation and Bone Formation by Influencing TAZ Transactivation via Complex Formation with NHERF1

(2009) W. Xing et al.   MOLECULAR AND CELLULAR BIOLOGY

Phase 1 study of the oral isotype specific histone deacetylase inhibitor MGCD0103 in leukemia

(2008) G. Garcia-Manero et al.   BLOOD

Histone deacetylase inhibitors: Mechanisms of cell death and promise in combination cancer therapy

(2008) Jennifer S. Carew et al.   CANCER LETTERS

TAZ Promotes Cell Proliferation and Epithelial-Mesenchymal Transition and Is Inhibited by the Hippo Pathway

(2008) Q.-Y. Lei et al.   MOLECULAR AND CELLULAR BIOLOGY